A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •1. Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
• •2. Active central nervous system metastases
• •3. Prior treatment with cluster of differentiation immune checkpoint blockade therapies or Bevacizumab
• •4. Has received a surgical operation within 4 weeks from the initial drug administration
• •5. Active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
• •6. Currently having or have had interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity
• •7. Any active infection requiring systemic anti-infective therapy within 14 days prior to study drug administration
• •8. Uncontrollable active infection(s)
• •9. History of immunodeficiency, including HIV antibody positive
• •10. active hepatitis B; or hepatitis C virus infections
• •11. Has bleeding tendency
• •12. History of severe cardiovascular diseases
• •13. Known gastrointestinal diseases as follows, Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or \> moderate esophageal varices
• •14. Pregnant or breastfeeding female